Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia
Autore:
Armstrong, WB; Kennedy, AR; Wan, XS; Atiba, J; McLaren, E; Meyskens, FL;
Indirizzi:
Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Dept Med, Orange, CA 92868 USA Univ Calif Irvine Orange CA USA 92868 Ctr, Dept Med, Orange, CA 92868 USA Univ Calif Irvine, Dept Otolaryngol, Orange, CA 92868 USA Univ Calif Irvine Orange CA USA 92868 t Otolaryngol, Orange, CA 92868 USA Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA Univ Penn Philadelphia PA USA 19104 iat Oncol, Philadelphia, PA 19104 USA
Titolo Testata:
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
fascicolo: 1, volume: 9, anno: 2000,
pagine: 43 - 47
SICI:
1055-9965(200001)9:1<43:SAOBIC>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
PROTEASE INHIBITOR; TRANSFORMATION INVITRO; DIETARY ADDITION; CANCER; CARCINOGENESIS; MICE; DIMETHYLHYDRAZINE; RADIATION; SUPPRESSION; PROTECTION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
41
Recensione:
Indirizzi per estratti:
Indirizzo: Meyskens, FL Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Dept Med,101 City Dr S,Bldg 23,Suite 406, Orange, CA 92868 USA Univ Calif Irvine 101 City Dr S,Bldg 23,Suite 406 Orange CA USA 92868
Citazione:
W.B. Armstrong et al., "Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia", CANC EPID B, 9(1), 2000, pp. 43-47

Abstract

The Bowman-Birk inhibitor (BBI) is a soybean-derived serine protease inhibitor and a potential cancer chemopreventive agent for humans. In this PhaseI clinical trial, BBI concentrate was administered as a single oral dose to 24 subjects with oral leukoplakia. Pharmacokinetics of BBI was analyzed, and subjects were monitored clinically for toxic effects, Subjects receivedbetween 25 and 800 chymotrypsin inhibitor units (CIU) of the compound in adose escalation trial. BBI was taken up rapidly, and a metabolic product of BBI was excreted in the urine within 24-48 h, No clinical or laboratory evidence of toxicity was observed in the study, Protease activity was also measured in buccal cells to evaluate usefulness as a biomarker, Single-dose BBI concentrate administered up to 800 CIU was well tolerated and appeared to be nontoxic, Further investigation in Phase II clinical trials is being done.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 15/07/20 alle ore 07:22:24